

Half-year Report

Released : 30 September 2025 7:00

RNS Number : 3030B
Ovoca Bio PLC
30 September 2025

Ovoca Bio PLC
30 September 2025

Ovoca Bio plc
("Ovoca" or the "Company")

Interim Results for the six months ended 30 June 2025

Dublin, Ireland, 30 September 2025 - Ovoca Bio announces its interim financial statements and report covering the six-months ending 30 June 2025.

Please click on the following link to view the full Half Year Report and extracts are set out at the end of this announcement:

[Ovoca News - Ovoca Bio](#)

CEO Statement

Today we have published Ovoca's financial statements covering the six-month period to the end of June 2025, which I encourage all stakeholders to read. On 7 May 2025 the Company entered into a conditional Letter of Intent ("LOI") to acquire 100% of Tadeen International Limited ("Tadeen"), a UK-registered company, which indirectly owns 100% of a portfolio of mineral exploration licenses in Morocco prospective for Copper and Silver (the "Proposed Acquisition"). The team at Ovoca has been working to complete the Proposed Acquisition and in due course further announcements will be made as we finalize the acquisition of Tadeen.

As at 30 June 2025, the Company had cash and cash equivalents amounting to €1,526 million (\$ 1,788 million) and we will continue to carefully manage our financial resources. The costs incurred during the period relate to the costs of work in relation to the Proposed Acquisition along with corporate costs.

I would like to thank the management team of the Company and the Board of Directors for their support.

End

For further information:

Ovoca Bio plc
Tim McCutcheon (Chief Executive Officer)
Tel +353 1 661 9819
info@ovocabio.com

Beaumont Cornish Limited (Nominated Adviser and Broker)
James Biddle/ Roland Cornish
Tel: +44 (0) 207 628 3396

Nominated Adviser Statement

Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated Adviser and is authorised and regulated in the United Kingdom by the Financial Conduct Authority. Beaumont Cornish's responsibilities as

Loss before tax	-	416	(1,187)	(750)
Income Tax	-	-	-	-
Loss after tax	-	416	(1,187)	(750)
Segment assets	-	-	1,561	1,561
Segment liabilities	-	-	(186)	(186)
Net assets	-	-	1,375	1,375
Period ended 30 June 2024		Fin- g losses/operational costs	Revenue cost costs	Admin costs/fin- costs
Administration expenses	(34)	(155)	(46)	(235)
Other gain/(loss)	-	(332)	(343)	(665)
Operating loss	(34)	(487)	(389)	(910)
Finance costs	-	(1)	(3)	(4)
Finance income	-	-	-	-
Loss before tax	(34)	(479)	(392)	(905)
Income Tax	-	-	-	-
Loss after tax	(34)	(479)	(392)	(905)
Segment assets	1,443	1,588	(631)	1,391
Segment liabilities	(19)	(339)	(3)	(61)
Net assets	1,424	1,249	(634)	1,330

6 Financial Instruments

The Group considers relevant aspects of financial instrument risk on an ongoing basis. Financial instrument risks primarily relates to foreign exchange risk, credit risk, liquidity risk and market risk as reported in the 31 December 2024 annual report.

	Unaudited	Audited	Unaudited	Audited
	30/06/2025	31/12/2024	30/06/2025	31/12/2024
	€'000	€'000	US\$'000	US\$'000
Financial assets not measured at fair value				
Cash and cash equivalents	1,526	2,586	1,706	2,610
Other debt instruments	135	146	156	154
	1,661	2,732	1,862	2,764
Financial liabilities not measured at fair value				
Trade and other payables	596	594	664	619
	596	594	664	619

The carrying amount of the financial assets and liabilities is considered a reasonable approximation of fair value:

- Other debt instruments
- Cash and cash equivalents
- Trade and other payables

7 Dividends

The company made no dividend during the period.

8 Events after the reporting period

There are no events after the reporting period that require to be reported.

9 Approval of the financial statements

The interim report was approved by the Board of Directors on 26 Sept 2025 and is included on the Company's website, www.avea.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IR EANNNAAXSEFA